Capricor Therapeutics (CAPR) Other Accumulated Expenses (2012 - 2026)

Capricor Therapeutics' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 1885.45% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 1885.45% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 622.1% from the prior year.
• Other Accumulated Expenses climbed to $4.0 million in Q1 2026 per CAPR's latest filing, from $3.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.0 million in Q1 2026 and bottomed at $10000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $145457.5 (2022), against an average of $1.0 million.
• Across the five-year window, Other Accumulated Expenses tumbled 88.79% in 2023 and surged 26121.55% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $89234.0 in 2022, then tumbled by 88.79% to $10000.0 in 2023, then jumped by 4257.12% to $435712.0 in 2024, then soared by 622.1% to $3.1 million in 2025, then grew by 27.27% to $4.0 million in 2026.
• Per Business Quant, the three latest CAPR Other Accumulated Expenses figures stand at $4.0 million (Q1 2026), $3.1 million (Q4 2025), and $2.6 million (Q3 2025).